SHC Quote, Financials, Valuation and Earnings

Fonar has a net margin of 5.95% compared to Sotera Health's net margin of 12.56%. Sotera Health's return on equity of 16.51% beat Fonar's return on equity of 6.13%.

Sotera Health has a consensus price target of $16.19, signalling upside risk potential of 21.44%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Sotera Health has higher upside potential than Fonar, analysts believe Sotera Health is more attractive than Fonar.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fonar has a beta of 1.210, suggesting its more volatile than the S&P 500 by 21.004%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

Sotera Health quarterly revenues are $285.5M, which are larger than Fonar quarterly revenues of $25M. Sotera Health's net income of $17M is higher than Fonar's net income of $3.1M. Notably, Sotera Health's price-to-earnings ratio is 53.32x while Fonar's PE ratio is 10.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 3.38x versus 0.95x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 5.95% compared to Sotera Health's net margin of -209.38%. Sotera Health's return on equity of 16.51% beat ProPhase Labs's return on equity of -59.59%.

Sotera Health has a consensus price target of $16.19, signalling upside risk potential of 21.44%. On the other hand ProPhase Labs has an analysts' consensus of -- which suggests that it could grow by 2819.82%. Given that ProPhase Labs has higher upside potential than Sotera Health, analysts believe ProPhase Labs is more attractive than Sotera Health.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.316, suggesting its less volatile than the S&P 500 by 131.62%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Sotera Health quarterly revenues are $285.5M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Sotera Health's net income of $17M is higher than ProPhase Labs's net income of -$6.6M. Notably, Sotera Health's price-to-earnings ratio is 53.32x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 3.38x versus 0.92x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of 5.95% compared to Sotera Health's net margin of 13.08%. Sotera Health's return on equity of 16.51% beat Veracyte's return on equity of -0.84%.

Sotera Health has a consensus price target of $16.19, signalling upside risk potential of 21.44%. On the other hand Veracyte has an analysts' consensus of -- which suggests that it could grow by 5.45%. Given that Sotera Health has higher upside potential than Veracyte, analysts believe Sotera Health is more attractive than Veracyte.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Veracyte has a beta of 1.690, suggesting its more volatile than the S&P 500 by 69.047%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

Sotera Health quarterly revenues are $285.5M, which are larger than Veracyte quarterly revenues of $115.9M. Sotera Health's net income of $17M is higher than Veracyte's net income of $15.2M. Notably, Sotera Health's price-to-earnings ratio is 53.32x while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 3.38x versus 7.31x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 5.95% compared to Sotera Health's net margin of -56.4%. Sotera Health's return on equity of 16.51% beat XWELL's return on equity of -71.82%.

Sotera Health has a consensus price target of $16.19, signalling upside risk potential of 21.44%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 351.61%. Given that XWELL has higher upside potential than Sotera Health, analysts believe XWELL is more attractive than Sotera Health.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XWELL has a beta of 2.426, suggesting its more volatile than the S&P 500 by 142.629%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Sotera Health quarterly revenues are $285.5M, which are larger than XWELL quarterly revenues of $8.4M. Sotera Health's net income of $17M is higher than XWELL's net income of -$4.8M. Notably, Sotera Health's price-to-earnings ratio is 53.32x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 3.38x versus 0.20x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.